BATM Advanced Communications Ld Appointment of Non-Executive Director (1871I)

TIDMBVC

RNS Number : 1871I

BATM Advanced Communications Ld

13 April 2022

LEI: 213800FLQUB9J289RU66

13 April 2022

BATM Advanced Communications Limited

("BATM" or "the Group")

Appointment of Non-Executive Director

BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, is pleased to announce the appointment of Dr. Avigdor Shafferman as a Non-Executive Director of the Company with immediate effect.

Dr. Avigdor Shafferman, aged 75, had an established career at the Israel Institute for Biological Research, a leading governmental applied research institute specialising in the fields of biology, medicinal chemistry and environmental sciences, where he worked for almost 40 years. Most recently, from 1995 until his retirement in 2013, he was General Director of the organistion. Other roles have included serving as a visiting professor in the University of California, San Diego at the biology department as well as a visiting senior research scientist at various leading research institutions in the United States in various medical areas, including vaccines. Dr. Shafferman holds a Ph.D. in physical chemistry from the Hebrew University of Jerusalem.

Previously, Dr. Shafferman served as an external director of the Group (as defined under Israeli law) from February 2015 to February 2018. External directors under Israeli law are appointed for terms of three years. With his new appointment as a Non-executive Director, Dr. Shafferman will be subject to annual re-election at the Group's annual general meeting.

Dr. Gideon Chitayat, Chairman of BATM, said: "On behalf of the Board, I would like to welcome Avigdor back to BATM. He made an excellent contribution to our business previously and we look forward to once again being able to leverage his wealth of knowledge and experience as we continue to advance our leading-edge medical diagnostics solutions."

There is no further information required to be disclosed in relation to Dr. Shafferman pursuant to Listing Rule 9.6.13 and Dr. Shafferman does not have any beneficial interest in BATM's ordinary shares.

Enquiries:

 
 
  BATM Advanced Communications 
Dr Zvi Marom, Chief Executive Officer                           [phone] 
Moti Nagar, Chief Financial Officer 
 
Shore Capital 
Mark Percy, Anita Ghanekar, James Thomas (Corporate Advisory)   [phone] 
 
Luther Pendragon 
Harry Chathli, Claire Norbury                                   [phone] 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOABRGDSBUBDGDD

(END) Dow Jones Newswires

April 13, 2022 02:01 ET (06:01 GMT)